Core Insights - Microbot Medical Inc. has appointed Paul Mullen as Vice President of Sales, marking the company's first commercial hire as it prepares for FDA clearance anticipated in Q2 2025 [1][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on developing the LIBERTY Endovascular Robotic System, which aims to redefine endovascular robotics and improve patient care globally [4] Appointment Details - Paul Mullen brings extensive experience in the endovascular medical device market, having previously served as Director of Sales at Inari Medical, which was acquired by Stryker Corporation for $4.94 billion [2] - Mullen's responsibilities will include building the sales strategy and infrastructure for a successful product launch following FDA clearance [1][3] Market Context - The endovascular space is critical for treating conditions such as deep vein thrombosis and pulmonary embolisms, with Mullen having successfully launched multiple innovative devices in this area [2] - The company aims to eliminate barriers to access for advanced robotic technologies in the endovascular field, potentially benefiting millions of patients [4]

Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation modelBRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical® and Corewell Health™ are working tog ...

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I preferred inve ...

Core Viewpoint - Microbot Medical Inc. has announced a registered direct offering and a concurrent private placement to raise approximately $13 million for the development of its LIBERTY Robotic System and other corporate purposes [1][3]. Group 1: Offering Details - The company will sell 6,103,289 shares of common stock at a price of $2.13 per share in a registered direct offering [1]. - In addition, the company will issue unregistered short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock, also at an exercise price of $2.13 per share [1]. - The closing of these offerings is expected to occur on or about February 11, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offerings will be used for the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System, as well as for expanding applications from the existing IP portfolio and for working capital [3]. Group 3: Regulatory Information - The common stock is being offered under a "shelf" registration statement previously filed with the SEC, which was declared effective on December 4, 2023 [4]. - The short-term series I preferred investment options are being issued in a private placement and have not been registered under the Securities Act [5]. Group 4: Company Overview - Microbot Medical Inc. is a clinical stage medical technology company focused on improving patient care through innovative solutions, including the development of the world's first single-use, fully disposable endovascular robotic system [7].

BRAINTREE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the acceptance of a late-breaking abstract that will be presented at the upcoming Society of Interventional Radiology (SIR) annual meeting, being held in Nashville, TN on March 29 - April 2, 2025. The data from the Company's ACCESS-PVI trial, a prospective, multicenter, single-arm trial evaluating the performance and safety of LIBERTY® in ...

Core Viewpoint - Microbot Medical Inc. has appointed Ms. Michal Ahuvia as the Director of Operations to enhance production efficiency and prepare for the commercial launch of the LIBERTY® Endovascular Robotic System, expected in Q2 2025 [1][3]. Group 1: Appointment and Role - Ms. Michal Ahuvia has over 20 years of experience in operations, focusing on process transformation, performance improvement, and supply chain management [2]. - In her new role, Ms. Ahuvia will be responsible for ramping up production and improving efficiencies as the company prepares for the LIBERTY® launch [1][3]. Group 2: Company Background - Microbot Medical Inc. is a pre-commercial stage medical technology company aiming to enhance patient care globally with its innovative single-use, fully disposable endovascular robotic system [3]. - The LIBERTY® system is designed to overcome traditional barriers to accessing advanced robotic systems in medical procedures [3]. Group 3: Leadership Perspective - Harel Gadot, Chairman and CEO, emphasized the importance of efficient production ramp-up as a critical part of the company's commercial strategy and future success [3]. - He expressed confidence in Ms. Ahuvia's ability to execute operational plans and meet commercial objectives [3].

Core Insights - Microbot Medical Inc. is transitioning into a commercially focused company with the election of David J. Wilson to the Board of Directors, who has extensive experience in the endovascular devices market [1][3] - The company is preparing for the commercial launch of its LIBERTY® Endovascular Robotic System, expected in the second quarter of 2025 [3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company aiming to improve care quality for patients and providers globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, designed to eliminate barriers to accessing advanced robotic systems [4] Leadership Background - David J. Wilson has over 30 years of global leadership experience in business strategy, operations, R&D, and product launches, including significant roles at Johnson and Johnson [2] - Prior to joining Microbot Medical, Wilson was the President of Global Plasma at Haemonetics Corporation and is currently the CEO of InnovHeart [2] Board Changes - Wilson replaces Yossi Bornstein, who served on the Board since before the company went public in 2016, with his term ending in December 2024 [4]

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred inve ...

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series H preferred investment options. The short-term series H ...

HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term series ...